Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the
treatments of MBC; however, the optimal dosing schedules for these combinations have not yet
been determined. The primary objective of this study is to compare the response rates of the
gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when
administered on a biweekly schedule in metastatic breast cancer.